WDWei Dai

Wei Dai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Dai has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis

    by Jianbo Peng, Shuo Fang, Meisheng Li, Yuxin Liu, Xiaolu Liang, Zuobiao Li, Gaohui Chen, Lijiao Peng, Nianping Chen, Lei Liu, et al.

    The aim of this study is to investigate certain genetic features of intrahepatic cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor tissues from the patients were subjected to next-generation sequencing of a multi-genes panel. Tumor mutation burden (TMB), mutated genes, copy number variants (CNVs), and pathway enrichment analysis were performed. The median TMB was 2.76 Mutation/Mb (range, 0–36.62 Mutation/Mb) in ICCA patients. The top two most commonly mutated genes in ICCA were KRAS (33%) and TP53 (25%). The co-mutations of KRAS and TP53 were 16.7% (2/12) in ICCA patients. Notably, patient P6 with the highest TMB did not have KRAS and TP53 mutations. Additionally, TP53 and/or KRAS alterations were significantly associated with poor progression-free survival than those with wild type (1.4 months vs 18 months). DNA damage repair and homologs recombinant repair deficiencies were significantly associated with high TMB in ICCA cases. In conclusion, we found that certain genetic mutations of TP53 and KRAS could predict poor prognosis in ICCA patients.


  • Open Access

    Pan-carcinogenic analysis of ITGA2 in human tumor carcinogenesis

    by YuXin Liu, Hua Li, LiangFang Yang, TingYun Shen, Lei Liu, Wei Deng, GuiHua Fang, Wei Dai

    Background: It is very important to understand and explore its carcinogenic effect for the study of effective therapeutic methods. Current studies have shown that ITGA2 plays an important role in some tumors, but it has not been reported in other human cancers, and no systematic pan-cancer analysis has been carried out. Method: In this study, we used the online databases,for example GEPIA, THE HUMAN PROTEIN Atlas (THPA) , UALCAN, CPTAC and TIMER, to analyze ITGA2 in HUMAN tumors by analyzing TCGA and GEO medium datasets. Results: Through the analysis of online database, we found that ITGA2 was differentially expressed in many kinds of tumors. There was a significant correlation between the differential expression of OS and DFS in hepatocellular carcinoma and Kidney renal clear cell carcinoma. At the same time, we also compared the degree of methylation between normal tissues and tumor tissues, and found that there were obvious methylation differences, such as liver cancer, cholangiocarcinoma, lung cancer and so on. We also evaluated the association between ITGA2 mutation and prognosis and found no significant association between ITGA2 mutation with OS. In addition, by predicting differences in the expression of ITGA2 in immunotherapy, we found that there were significant differences in the expression of ITGA2 in urothelial carcinoma, and explored the role and significance of ITGA2 in immune infiltration and biological process. Conclusion: ITGA2 has been shown to play an important role in carcinogenesis in human tumors by pan-cancer analysis.